Lion Point Capital’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Lion Point Capital’s Portfolio STSA Stock Details STSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-319,742	Closed	-$223K	–	36
2023 Q1	$223K	Buy	+319,742	New	+$294K	0.09%	25

Lion Point Capital's STSA Position: Q2 2023 in Review

Lion Point Capital sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q2 2023, closing a stake of 319,742 shares — an estimated $223K sold.

Lion Point Capital first reported a position in STSA in Q1 2023 and held it in 1 quarter. The position peaked at $223K in Q1 2023. 0 funds tracked by Wall St. Rank hold STSA as of Q2 2023.

Lion Point Capital reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Lion Point Capital sold 319,742 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $223K.
Lion Point Capital first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
Lion Point Capital's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $223K in Q1 2023.
0 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Lion Point Capital's 13F filing for Q2 2023, filed 14 Aug 2023.